Robenacoxib, sold under the brand name Onsior, is a nonsteroidal anti-inflammatory drug (NSAID) used in veterinary medicine for the relief of pain and inflammation in cats and dogs. It is a COX-2 inhibitor (coxib). Chemically a synthetic coxib class compound, robenacoxib exhibits preferential inhibition of cyclooxygenase 2 relative to cyclooxygenase 1, providing analgesic and anti-inflammatory efficacy with reduced impact on COX-1 dependent homeostatic processes. The active pharmaceutical ingredient is formulated for oral tablets and injectable solutions; it is characterized by rapid absorption, high plasma protein binding, hepatic metabolism to polar metabolites and elimination via renal and biliary routes. Typical pharmacokinetic features include a short plasma half-life but sustained residence in inflammatory exudate and target tissues, which supports once-daily dosing in many labelled indications. Analytical control of the API emphasizes assay purity, structural identification by HPLC and mass spectrometry, and stability under controlled storage conditions.
Parent: Robenacoxib
Parent: Robenacoxib
Parent: Robenacoxib
Parent: Robenacoxib
Parent: Robenacoxib
Parent: Robenacoxib
Parent: Robenacoxib
Typical API acceptance criteria for robenacoxib used in regulatory dossiers or quality specifications include assay 98.0 to 102.0 percent on a dried basis; identified related compounds RC-1, RC-2 and RC-3 limited to not more than 0.5 percent w/w each; specified degradant RC-4 limited to not more than 0.2 percent w/w; any unspecified impurity not greater than 0.10 percent w/w; total impurities not to exceed 2.0 percent w/w. Potential genotoxic impurities are controlled below a conservative threshold, typically <0.05 percent w/w for individual genotoxic-related species. Typical ancillary quality limits include water content by Karl Fischer <=0.5 percent, heavy metals <=20 ppm, and residual solvents controlled per ICH Q3C (for example methanol and toluene limits applied as class 2 solvents per supplier dossier). These specification ranges are representative controls commonly applied by manufacturers and may vary according to the specific regulatory filing or pharmacopoeial monograph.
Robenacoxib is used in veterinary practice to control pain and inflammation associated with acute musculoskeletal disorders and perioperative pain in cats and dogs. Indications and duration of use depend on the species and product formulation and follow the approved label established from controlled clinical studies.
Robenacoxib is not approved for human use. If humans are exposed, the pharmacologic effect would be COX-2 inhibition with the potential for typical NSAID-related effects such as gastrointestinal irritation, renal function changes, hypersensitivity reactions and changes in platelet function. Any human exposure should be managed by a healthcare professional and reported to appropriate medical services.
The 3 day limitation on some Onsior labels reflects the duration evaluated in pivotal clinical trials supporting that specific indication, typically short-term postoperative pain control. Regulatory approvals restrict use to the studied duration to align demonstrated efficacy and safety data. Longer administrations increase the need for additional safety data due to the known class risks of NSAIDs such as renal, hepatic and gastrointestinal adverse events.
Common adverse effects reported in dogs include vomiting, diarrhea, decreased appetite, lethargy and transient changes in laboratory markers of renal or hepatic function. Less common but serious events include gastrointestinal ulceration, gastrointestinal perforation, renal impairment and hypersensitivity. Risk is higher when robenacoxib is used concurrently with other NSAIDs, corticosteroids, in dehydrated animals, or in animals with pre-existing renal or hepatic disease. Monitoring and adherence to label contraindications and dosing guidance reduce risk.
